Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

Next-generation DNA sequencing technology has dramatically advanced clinical oncology
through the identification of therapeutic targets and molecular biomarkers, leading to the …

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …

Pharmacological inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are now an
established standard of care for patients with advanced hormone receptor-positive breast …

In the commonly accepted paradigm for control of the mammalian cell cycle, sequential
cyclin-dependent kinase (CDK) and cyclin activities drive the orderly transition from G1 to S …

Purpose: Despite promising activity in hematopoietic malignancies, efficacy of the B-cell
lymphoma 2 (BCL2) inhibitor venetoclax in solid tumors is unknown. We report the …

Abstract Cyclin-dependent kinase 2 (CDK2) is thought to play an important role in driving
proliferation of certain cancers, including those harboring CCNE1 amplification and breast …

The interaction of RB with chromatin is key to understanding its molecular functions. Here,
for first time, we identify the full spectrum of chromatin-bound RB. Rather than exclusively …

While many germline cancer risk variants have been identified through genome-wide
association studies (GWAS), the mechanisms by which these variants operate remain …

The emergence of CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, has
revolutionized the treatment landscape for hormone receptor-positive breast cancer. These …